Gain Therapeutics, Inc. (NASDAQ:GANX) Sees Large Drop in Short Interest

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) was the recipient of a significant decrease in short interest in February. As of February 28th, there was short interest totalling 348,800 shares, a decrease of 24.5% from the February 13th total of 462,200 shares. Based on an average trading volume of 232,700 shares, the short-interest ratio is currently 1.5 days. Approximately 1.4% of the company's stock are short sold.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on GANX. Roth Mkm reissued a "buy" rating and set a $7.00 price objective on shares of Gain Therapeutics in a report on Tuesday, December 24th. Scotiabank started coverage on Gain Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $12.00 price target for the company. HC Wainwright restated a "buy" rating and set a $8.00 price objective on shares of Gain Therapeutics in a research note on Monday. Finally, Roth Capital upgraded Gain Therapeutics to a "strong-buy" rating in a research report on Thursday, December 5th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $8.20.

Gain Therapeutics Stock Performance

NASDAQ GANX traded down $0.15 during trading hours on Thursday, reaching $2.32. The company's stock had a trading volume of 304,299 shares, compared to its average volume of 279,574. The stock has a market cap of $61.43 million, a PE ratio of -2.15 and a beta of 0.14. The business has a 50-day simple moving average of $2.23 and a 200 day simple moving average of $2.01. Gain Therapeutics has a 52 week low of $0.89 and a 52 week high of $4.63. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.04.

Remove Ads

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sprott Inc. bought a new stake in Gain Therapeutics in the 4th quarter valued at about $30,000. Benedict Financial Advisors Inc. acquired a new stake in Gain Therapeutics in the 4th quarter valued at approximately $35,000. Bridgeway Capital Management LLC acquired a new position in Gain Therapeutics during the 4th quarter worth $65,000. Northern Trust Corp lifted its holdings in Gain Therapeutics by 88.2% in the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company's stock worth $183,000 after purchasing an additional 39,642 shares during the period. Finally, Marshall Wace LLP bought a new position in Gain Therapeutics in the 4th quarter valued at about $198,000. Institutional investors and hedge funds own 11.97% of the company's stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.